Journal
MOLECULAR CELL
Volume 22, Issue 2, Pages 159-168Publisher
CELL PRESS
DOI: 10.1016/j.molcel.2006.03.029
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA103866] Funding Source: Medline
- NIAID NIH HHS [R01 AI47389] Funding Source: Medline
- NIGMS NIH HHS [T32 GM007753] Funding Source: Medline
Ask authors/readers for more resources
The drug rapamycin has important uses in oncology, cardiology, and transplantation medicine, but its clinically relevant molecular effects are not understood. When bound to FKBP12, rapamycin interacts with and inhibits the kinase activity of a multiprotein complex composed of mTOR, mLST8, and raptor (mTORC1). The distinct complex of mTOR, mLST8, and rictor (mTORC2) does not interact with FKBP12-rapamycin and is not thought to be rapamycin sensitive. mTORC2 phosphorylates and activates Akt/PKB, a key regulator of cell survival. Here we show that rapamycin inhibits the assembly of mTORC2 and that, in many cell types, prolonged rapamycin treatment reduces the levels of mTORC2 below those needed to maintain Akt/PKB signaling. The proapoptotic and antitumor effects of rapamycin are suppressed in cells expressing an Akt/PKB mutant that is rapamycin resistant. Our work describes an unforeseen mechanism of action for rapamycin that suggests it can be used to inhibit Akt/PKB in certain cell types.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available